The Drug Pricing Shakeout

Ongoing public scrutiny of US drug prices has begun to limit the pricing power pharmaceutical companies have enjoyed for decades, according to Goldman Sachs Research’s Jami Rubin—a trend she calls “The Drug Pricing Shakeout.” She discusses early signs of pricing restraint she’s seen in the industry, as well as what could be ahead from the Trump Administration.